Anticancer Agent “TASFYGO Tablets 35mg” (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
TOKYO, Nov 20, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor “TASFYGO® Tablets...
